OTC · Biotechnology

Anebulo Pharmaceuticals, Inc. (ANEB) Stock

$0.34 +0.00% OTC: ANEB Healthcare

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity.

Valuation

MetricValue
Price$0.34
Market Cap$13.72M
P/E Ratio-1.73
P/B Ratio1.74
P/S Ratio0.00
EPS (TTM)$-0.25
52-Week High$3.42
52-Week Low$0.01
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-74.58%
ROA-84.68%
ROCE-102.66%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio16.71

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-4.0M$-7.0M$-12.0M$-8.0M$-9.0M
Net Profit$-30.0M$-7.0M$-12.0M$-8.0M$-8.0M
EPS$-1.30$-0.29$-0.47$-0.32$-0.25
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$22.0M$16.0M$12.0M$4.0M$12.0M
Total Liabilities$0$1.0M$1.0M$0$0
Cash$20.0M$15.0M$11.0M$3.0M$12.0M
Borrowings$0$0$0$0$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-5.0M$-5.0M$-10.0M$-8.0M$-6.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$-1.0M$0$0$0$0
Net Cash Flow$17.0M$-5.0M$-3.0M$-8.0M$9.0M
Free Cash Flow$-5.0M$-5.0M$-10.0M$-8.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.04
EV / EBITDA-0.63
FCF Yield-42.57%
Quick Ratio16.71
Interest Coverage-30.60
Return 1Y-79.76%
Return 3Y-86.61%
Return 5Y-95.21%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLNNClene Inc. $5.29 -1.86% -1.66 $54.53M 0.00%
COYA $4.00 -6.21% -2.62 $72.84M 0.00%
ESLAEstrella Immunopharma, Inc. $0.78 +0.06% -2.25 $33.59M 0.00%
IMMX $8.55 +4.65% -9.96 $465.14M 0.00%
MGNX $3.78 +3.00% -2.92 $240.27M 0.00%

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.

Anebulo Pharmaceuticals, Inc. is headquartered in US.

Anebulo Pharmaceuticals, Inc. (ANEB) stock trades at $0.34 with a market capitalization of $13.72M. The stock is valued at a price-to-earnings (P/E) ratio of -1.73, price-to-book of 1.74, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $3.42, and currently trades 90.1% below its 52-week high.

On profitability, Anebulo Pharmaceuticals, Inc. generates a return on equity (ROE) of -74.58%, return on capital employed of -102.66%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.anebulo.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides